SNDX

Syndax Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

9.980

+0.06(0.605%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.005

Open

9.9361

VWAP

9.78

Vol

1.70M

Mkt Cap

858.75M

Low

9.490

Amount

16.60M

EV/EBITDA(TTM)

Total Shares

84.99M

682.53M

EV/OCF(TTM)

P/S(TTM)

19.48

Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

27.09M

+674.1%

-0.995

+24.39%

33.24M

+165.92%

-0.928

-5.34%

-0.877

-20.3%

Estimates Revision

The market is revising Upward the revenue expectations for Syndax Pharmaceuticals, Inc. (SNDX) for FY2025, with the revenue forecasts being adjusted by 37.95% over the past three months. During the same period, the stock price has changed by -27.79%.

Revenue Estimates for FY2025

Revise Upward

+37.95%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.24%

In Past 3 Month

Stock Price

Go Down

-27.79%

In Past 3 Month

10 Analyst Rating

217.33% Upside

Wall Street analysts forecast SNDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNDX is 31.67 USD with a low forecast of 17.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

217.33% Upside

Current: 9.980

Low

17.00

Averages

31.67

High

45.00

217.33% Upside

Current: 9.980

Low

17.00

Averages

31.67

High

45.00

UBS

David Dai

Buy

downgrade

$37 -> $35

2025-07-15

Reason

UBS

David Dai

Price Target

$37 -> $35

2025-07-15

downgrade

Buy

Reason

UBS analyst David Dai lowered the firm's price target on Syndax to $35 from $37 and keeps a Buy rating on the shares. UBS expects Syndax to report in-line Q2 results with $25M in Revuforj sales and $2.7M in Niktimvo revenue, but thinks Niktimvo sales could surprise to the upside even the strong Q1 launch, the analyst tells investors in a research note.

Goldman Sachs

Corinne Johnson

initiated

$18

2025-07-10

Reason

Goldman Sachs

Corinne Johnson

Price Target

$18

2025-07-10

initiated

Reason

Goldman Sachs analyst Corinne Johnson initiated coverage of Syndax with a Buy rating and $18 price target, implying 100% upside potential. The firm's positive view is based on the near-term and peak revenue opportunity for Revuforj, Syndax's wholly-owned lead drug currently approved for the treatment of relapsed/refractory acute myeloid leukemia patients. It estimates peak sales at $1.1B before considering potential use in the frontline setting.

JP Morgan

Anupam Rama

Buy

Maintains

$39 → $41

2025-03-20

Reason

JP Morgan

Anupam Rama

Price Target

$39 → $41

2025-03-20

Maintains

Buy

Reason

JPMorgan raised the firm's price target on Syndax to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 U.S. hematologists to better understand the launch prospects of Revuforj in relapsed/refractory KMT2A acute leukemias and NPM1-mutated acute myeloid leukemia. Overall, surveyed physicians provided high ratings related to the clinical profile of Revuforj in both indications, the analyst tells investors.

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

$51

2025-03-04

Reason

HC Wainwright & Co.

Edward White

Price Target

$51

2025-03-04

Reiterates

Strong Buy

Reason

Citigroup

Yigal Nochomovitz

Strong Buy

Maintains

$45 → $42

2025-03-04

Reason

Citigroup

Yigal Nochomovitz

Price Target

$45 → $42

2025-03-04

Maintains

Strong Buy

Reason

Citi lowered the firm's price target on Syndax to $42 from $45 and keeps a Buy rating on the shares post the Q4 report. The firm says the stock's "non-reaction" to Syndax's first print for Revuforj that handily beat consensus reflects the lack of incremental buyers who see relapsed or refractory KMT2A-rearranged leukemia as too narrow despite first-to-market advantage and early strong commercial execution. Citi believes it may take time for the NPM1 launch to "move the needle."

JP Morgan

Anupam Rama

Buy

Maintains

$35 → $39

2025-03-04

Reason

JP Morgan

Anupam Rama

Price Target

$35 → $39

2025-03-04

Maintains

Buy

Reason

JPMorgan raised the firm's price target on Syndax to $39 from $35 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology group post the Q4 reports.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Syndax Pharmaceuticals Inc (SNDX.O) is -2.71, compared to its 5-year average forward P/E of -7.84. For a more detailed relative valuation and DCF analysis to assess Syndax Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-7.84

Current PE

-2.71

Overvalued PE

-2.47

Undervalued PE

-13.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.23

Current EV/EBITDA

-2.37

Overvalued EV/EBITDA

3.70

Undervalued EV/EBITDA

-10.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

424.69

Current PS

5.89

Overvalued PS

1200.19

Undervalued PS

-350.81

Financials

Annual

Quarterly

FY2025Q1

20.04M

Total Revenue

FY2025Q1

YoY :

+5.03%

-83.51M

Operating Profit

FY2025Q1

YoY :

+17.19%

-84.85M

Net Income after Tax

FY2025Q1

YoY :

+15.29%

-0.98

EPS - Diluted

FY2025Q1

YoY :

+13.90%

-95.16M

Free Cash Flow

FY2025Q1

95.58

Gross Profit Margin - %

FY2025Q1

-655.32

FCF Margin - %

FY2025Q1

-423.34

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

82.0K

USD

3-6

Months

117.6K

USD

6-9

Months

336.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

241.9K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.7M

Volume

6-9

Months

11.4M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.5M

Volume

Months

6-9

4.1M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

82.0K

USD

3-6

Months

117.6K

USD

6-9

Months

336.2K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

241.9K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

SNDX News & Events

Events Timeline

2025-06-24 (ET)

2025-06-24

16:07:56

Syndax granted priority review for Revuforj sNDA by FDA

2025-06-12 (ET)

2025-06-12

12:07:17

Syndax reports publication of revumenib data from BEAT AML trial

2025-06-12

07:05:53

Syndax announces new data from AUGMENT-101 trial of Revuforj

News

4.0

07-11TipRanks

SNDX, NUVB, AURA : 3 Russell 2000 Stocks Analysts Say Could Soar Over 200%

6.0

07-10Benzinga

Goldman Sachs Initiates Coverage On Syndax Pharmaceuticals with Buy Rating, Announces Price Target of $18

9.0

06-25NASDAQ.COM

FDA Grants Priority Review To Syndax's Revuforj For R/R MNPM1 Acute Myeloid Leukemia Treatment

People Also Watch

PennyMac Mortgage Investment Trust

Lexinfintech Holdings Ltd

Capital Clean Energy Carriers Corp

Amalgamated Financial Corp

Custom Truck One Source Inc

6.160

USD

-0.48%

FAQ

What is Syndax Pharmaceuticals Inc (SNDX) stock price today?

The current price of SNDX is 9.98 USD — it has increased 0.6 % in the last trading day.

SNDX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

SNDX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Syndax Pharmaceuticals Inc (SNDX) stock price today?

What is Syndax Pharmaceuticals Inc (SNDX)'s business?

What is the price predicton of SNDX Stock?

What is Syndax Pharmaceuticals Inc (SNDX)'s revenue for the last quarter?

What is Syndax Pharmaceuticals Inc (SNDX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Syndax Pharmaceuticals Inc (SNDX)'s fundamentals?

How many employees does Syndax Pharmaceuticals Inc (SNDX). have?

What is Syndax Pharmaceuticals Inc (SNDX) market cap?